The "Comparative Growth Assay": Examining the Interplay of Anti-cancer Agents with Cells Carrying Single Gene Alterations

Neoplasia

Volumn 1, Issue 4, 1999, Pages 356-367

  Hausner, Petr ^b   Venzon, David J ^a   Grogan, Liam ^a   Kirsch, Ilan R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

BCRP; Chemosensitivity; Growth assay; Mismatch repair; Multiagent resistance

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTIBIOTIC G 418; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; FLUORESCENT DYE; GENTAMICIN; GREEN FLUORESCENT PROTEIN; METHYLNITRONITROSOGUANIDINE; MITOXANTRONE; PHOTOPROTEIN; TUMOR PROTEIN;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; CELL DIVISION; COCULTURE; COLON TUMOR; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MUTATION; RADIATION EXPOSURE; RADIATION RESPONSE; TIME;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL DIVISION; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT DYES; GENETIC VECTORS; GENTAMICINS; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; METHYLNITRONITROSOGUANIDINE; MITOXANTRONE; MUTATION; NEOPLASM PROTEINS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033206041     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900047     Document Type: Article

References (50)

1. Bosanquet AG, Burlton AR, Bell PB, and Harris AL (1997). Ex vivo cytotoxic drug evaluation by DISC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. Br J Cancer 76, 511-518.
2. Weinstein JN, Myers TG, PM OC, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wirtes RE, and Paull KD (1997). An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349.
3. Chalfie M, Tu Y, Euskirchen G, Ward WW, and Prasher DC (1994). Green fluorescent protein as a marker for gene expression. Science 263, 802-805.
4. Prasher DC (1995). Using GFP to see the light. Trends Genet 11, 320-323.
5. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, and Howell SB (1997). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57, 1841-1845.
6. Fink D, Nebel S, Norris PS, Aebi S, Kim HK, Haas M, and Howell SB (1998). The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br J Cancer 77, 703-708.
7. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, and Boland CR (1994). Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54, 4308-4312.
8. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95, 15665-15670.
9. Modrich P (1991). Mechanisms and biological effects of mismatch repair. Annu Rev Genet 25, 229-253.
10. Modrich P (1995). Mismatch repair, genetic stability and tumour avoidance. Philos Trans R Soc London B Biol Sci 347, 89-95.
11. Fishel R, and Kolodner RD (1995). Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5, 382-395.
12. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, and Perucho M (1993). Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363, 558-561.
13. Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, Papadopolous N, Peltomaki P, de la Chapelle A, Hamilton SR, et al. (1995). Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 9, 48-55.
14. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, and Anthoney DA (1997). hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15, 45-52.
15. Nicolaides NC, Liftman SJ, Modrich P, Kinzler KW, and Vogelstein B (1998). A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol 18, 1635-1641.
16. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, and Modrich P (1993). An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90, 6424-6428.
17. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, and Howell SB (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56, 3087-3090.
18. Drummond JT, Anthoney A, Brown R, and Modrich P (1996). Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271, 19645-19648.
19. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, and Howell SB (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56, 4881-4886.
20. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, and Mace R (1996). Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273, 1109-1111.
21. Mello JA, Acharya S, Fishel R, and Essigmann JM (1996). The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol 3, 579-589.
22. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, and Brown R (1996). Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56, 1374-1381.
23. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, and Doyle LA (1999). Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91, 429-433.
24. Take Y, Kumano M, Teraoka H, Nishimura S, and Okuyama A (1996). DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun 221, 207-212.
25. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, and Garcia AM (1995). Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55, 5310-5314.
26. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, and Vogelstein B (1995). Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55, 5548-5550.
27. Chakrabarty S, Chen JW, Chen XY, Trujillo JM, and Lin PF (1992). Modulation of differentiation-related responses in human colon carcinoma cells by protein kinase inhibitor H-7. Anticancer Res 12, 97-104.
28. Zorbas MA, and Yeoman LC (1993). Growth control in a human colon carcinoma cell line mediated by cell-associated transforming growth factor-alpha (TGF alpha). Exp Cell Res 206, 49-57.
29. Sun L, Wu S, Coleman K, Fields KC, Humphrey LE, and Brattain MG (1994). Autocrine transforming growth factor-beta 1 and beta 2 expression is increased by cell crowding and quiescence in colon carcinoma cells. Exp Cell Res 214, 215-224.
30. Zhang G, Gurtu V, and Kain SR (1996). An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res Commun 227, 707-711.
31. Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M, and Boland CR (1996). Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N-nitro-N-nitrosoguanidine. J Clin Invest 98, 199-206.
32. Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB, and Sidransky D (1994). Frequent microsatellite instability in primary small cell lung cancer. Cancer Res 54, 2098-2101.
33. Kim H, Jen J, Vogelstein B, and Hamilton SR (1994). Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145, 148-156.
34. Ishwad CS, Ferrell RE, Rossie KM, Appel BN, Johnson JT, Myers EN, Law JC, Srivastava S, and Gollin SM (1995). Microsatellite instability in oral cancer. Int J Cancer 64, 332-335.
35. Huddart RA, Wooster R, Harwich A, and Cooper CS (1995). Microsatellite instability in human testicular germ cell tumours. Br J Cancer 72, 642-645.
36. Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, Fujiwara T, Jen J, Kinzler KW, Wyllie AH, et al. (1995). Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1, 348-352.
37. Suzuki H, Komiya A, Aida S, Akimoto S, Shiraishi T, Yatani R, Igarashi T, and Shimazaki J (1995). Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn J Cancer Res 86, 956-961.
38. Herfarth KK, Kodner IJ, Whelan AJ, Ivanovich JL, Bracamontes JR, Wells SA Jr, and Goodfellow PJ (1997). Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability. Genes Chromosomes Cancer 18, 42-49.
39. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, and Kolodner R (1997). Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57, 808-811.
40. King BL, Peng HQ, Goss P, Huan S, Bronson D, Kacinski BM, and Hogg D (1997). Repeat expansion detection analysis of (CAG)n tracts in tumor cell lines, testicular tumors, and testicular cancer families. Cancer Res 57, 209-214.
41. Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Nystrom-Lahti M, Seruca R, David L, Holm R, Ryberg D, Haugen A, et al. (1993). Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 53, 5853-5855.
42. Holzman D (1996). Mismatch repair genes matched to several new roles in cancer. J Natl Cancer Inst 88, 950-951.
43. Davis TW, Wilson-Van Patten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C, Garces C, Boland CR, Kinsella TJ, Fishel R, and Boothman DA (1998). Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 58, 767-778.
44. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, and Modrich P (1997). Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 57, 2933-2936.
45. Shellard SA, Hosking LK, and Hill BT (1994). Characterisation of the unusual expression of cross-resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line. Biochem Pharmacol 47, 775-779.
46. Hamaguchi K, Godwin AK, Yakushiji M, PJ OD, Ozols RF, and Hamilton TC (1993). Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53, 5225-5232.
47. Fritzell JA, Narayanan L, Baker SM, Bronner CE, Andrew SE, Prolla TA, Bradley A, Jirik FR, Liskay RM, and Glazer PM (1997). Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res 57, 5143-5147.
48. + tumor cells. Cell 75, 1227-1236.
49. Kaye SB (1996). Ovarian cancer, from the laboratory to the clinic: challenges for the future. Ann Oncol 7, 9-13.
50. Wei Q, Bondy ML, Mao L, Gaun Y, Cheng L, Cunningham J, Fan Y, Bruner JM, Yung WK, Levin VA, and Kyritsis AP (1997). Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 57, 1673-1677.